{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 109 of 122', 'REFERENCE', 'Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, Sicherer S, Teuber SS, Burks AW, et al. Standardizing', 'double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma &', 'Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus report. J Allergy', 'Clin Immunol. 2012;130(6):1260-74.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 110 of 122', 'Appendix 3: Study Schedule of Activities for All Subjects: Screening (Days -28 to -1)', 'Activity', 'Comments', 'General', 'Complete screening procedures within 28 days after obtaining signed consent.', 'Informed consent, screening number', 'Obtain consent (and assent if applicable) before performing any study-specific procedures. Ensure consent is on', 'current version of form reviewed by the ethics committee.', 'Demographics, medical history', 'Includes allergy history (including anaphylactic reactions) and symptoms, diet/food allergen history, and proxy- and', 'self-reported severity of peanut allergy. Also includes family history of peanut and other food allergy.', 'Weight, height', 'Vital signs', 'Measure blood pressure, heart rate, and temperature.', 'ACT/C-ACT, SCORAD, TNSS', 'For subject with asthma: ACT for subject aged > 12 years; C-ACT for subject aged 4-11 years and parent/caregiver.', 'For subject with atopic dermatitis: SCORAD.', 'For subject with allergic rhinitis: TNSS (short form).', 'PEFR and/or spirometry (FEV1)', 'For subject aged > 6 years, obtain PEFR; record the best result of 3 attempts. For subject with asthma, obtain', 'spirometry (FEV1); record the best result of 3 attempts (if unable to successfully obtain, record attempts and', 'investigator assessment).', 'For subject aged 4-5 years, obtain PEFR; record results (if unable to successfully obtain, record attempts and', 'investigator assessment). Reliable performance is not required for study eligibility at the discretion of the investigator.', 'Asthma evaluation', 'For subject with asthma. Evaluate asthma severity per NHLBI 2007 criteria (Table 19).', 'Food allergy instruction', 'Provide food/peanut allergy education (including recognition of an allergic reaction, symptoms of anaphylaxis,', 'administration of epinephrine auto-injector, anaphylaxis action plan, ways to minimize accidental exposure to peanut)', 'per standard of care at the study site. Verify that subject has an epinephrine auto-injector, including appropriate dose', \"and expiry. Instruct subject to avoid peanut during the study. Document the discussion in the subject's source records.\", 'Physical examination', 'Assess systems (eg, general appearance, head, eyes, ears, nose, mouth, skin, heart, lungs, lymph nodes,', 'gastrointestinal, genitourinary, neurologic, and skeletal).', 'Pretreatment adverse event review', 'Record adverse event information (including allergy symptoms) from the time of signed informed consent/assent.', 'Concomitant medications review', 'Record all medications taken within 90 days before screening.', '& instruction', 'Instruct subject to discontinue antihistamines at least 5 half-lives of the medication before the skin prick test and', \"randomization. Review the prescribing information to determine the half-life of each medication for the subject's\", 'relevant age group.', 'Skin prick test', 'Measure wheal diameter for peanut extract.', 'Laboratory Evaluations (Central)', 'Refer to the laboratory manual for sample collection and processing.', 'Hematology, immunology', 'Complete blood count with differential. Total, peanut-specific, and peanut component-specific IgE.', 'Serum pregnancy test', 'For all females of childbearing potential.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 111 of 122', 'Activity', 'Comments', 'Blood sample for basophil', 'activation test (BAT)', 'Eligibility Confirmation', 'Eligibility confirmation', 'Confirm eligibility after completion of all screening activities.', 'After confirmation of eligibility, randomization must not occur until after completion of baseline questionnaires per', 'Appendix 4 and Appendix 6.', 'ACT, Asthma Control Test; C-ACT, Childhood Asthma Control Test; FEV1, forced expiratory volume in the first second of expiration; Ig,', 'immunoglobulin;', 'NHLBI, National Heart, Lung, and Blood Institute; PEFR, peak expiratory flow rate; SCORAD, scoring atopic dermatitis; TNSS, Total Nasal Symptom', 'Score.']\n\n###\n\n", "completion": "END"}